Pharmaceutical

GSK and CureVac restructure mRNA vaccine development deal

GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.

Jul 4, 2024 - 04:00
GSK and CureVac restructure mRNA vaccine development deal
GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.
Read the original article

Tags:

Previous Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

Next Article

Protecting your drug products: Strategies for preventing metal contamination in ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘We’re absolutely making it too hard’: The complexity of adult immunization delivery hinders vaccine uptake

‘We’re absolutely making it too hard’: The complexity o...

Oct 26, 2023

Beyond approval: Patients pursue alternate paths to get rare disease treatments

Beyond approval: Patients pursue alternate paths to get...

Feb 28, 2024

STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data

STAT+: Dana-Farber cancer researchers moving to retract...

Jan 20, 2024